Immune Ageing Biomarkers

Key Takeaways

Immune ageing biomarkers describe age-related remodeling of immune cell composition, inflammatory signaling, receptor diversity, and immune-cell function rather than one single process. [1] [2]
Common measures include naive and memory T cell balance, CD4/CD8 ratio, senescence-associated T cell markers, cytokines, chemokines, and high-dimensional immune age scores. [3] [4] [5]
Immune age models such as IMM-AGE and inflammatory age clocks can predict cohort-level outcomes, but they remain model outputs rather than direct measurements of whole-body biological age. [6] [7] [8]
Interpretation is limited by infection history, cytomegalovirus status, assay platform, medication use, chronic disease, and population differences. [1] [9] [10]

Immune ageing biomarkers are measurements used to summarize how the immune system changes with age. They can include cell counts, flow-cytometry markers, cytokines, chemokines, gene-expression patterns, immune-receptor repertoire features, and multi-marker immune age models. [1] [2] [6]

Who This Is Useful For

This page is useful for readers comparing immune ageing, inflammaging, immunosenescence, and biological age claims that use blood immune measurements. It is especially relevant when interpreting papers that report immune age scores, T cell senescence markers, cytokine panels, or single-cell immune profiles. [1] [2] [6] [8]

What Immune Ageing Biomarkers Measure

Immune ageing is not simply a weaker immune system. Reviews describe a remodeling process that involves reduced production of new naive lymphocytes, accumulation of differentiated memory and effector cells, altered innate immune responses, chronic low-grade inflammatory signaling, and changes in tissue immune environments. [1] [2] [11]

The adaptive immune system is often central in biomarker studies because thymic involution reduces new T cell output across life, while repeated antigen exposure can expand memory and highly differentiated T cell populations. These processes can narrow immune-receptor diversity and shift the balance between naive and memory compartments. [3] [4] [5]

Common Biomarker Types at a Glance

Biomarker Type	What It Measures	Why Researchers Use It	Main Limitation
T cell subset composition	Naive, central memory, effector memory, and terminally differentiated T cell balance	Captures adaptive immune remodeling linked to thymic output and antigen history	Strongly affected by infections such as cytomegalovirus and by cohort composition
Senescence-associated T cell markers	Patterns such as CD28 loss and higher CD57 or KLRG1 expression	Used to identify differentiated or senescence-like T cell states	Marker meaning depends on cell type, activation state, and assay design
Inflammatory proteins	Cytokines, chemokines, and acute-phase markers such as IL-6, TNF-alpha, CRP, and CXCL9	Reflects inflammatory ageing and immune signaling in blood	Non-specific; levels can shift with infection, adiposity, disease, and stress
Immune age scores	High-dimensional models built from multiple immune features	Summarizes complex immune profiles into a score linked to age or outcomes	Model outputs depend on training data, platform, and prediction target
Single-cell immune profiles	Cell-type composition, transcriptional states, receptor features, and cell heterogeneity	Maps immune ageing at higher resolution than bulk blood markers	Expensive, analytically complex, and sensitive to preprocessing choices

T Cell Markers and Immune Repertoire Ageing

T cell measures are widely used because ageing changes the supply, maintenance, and differentiation of T cells. Thymic involution lowers new naive T cell output, and older adults often show fewer naive T cells alongside more differentiated memory or effector populations. [3] [4] [5]

Flow-cytometry studies often use markers such as CD28, CD57, and KLRG1 to describe senescence-like or terminally differentiated T cell states. A systematic review of T cell immunosenescence reported that CD28 loss and CD57 expression were among the main markers used, although no single marker defines immune ageing by itself. [5]

CD4/CD8 ratio and cytomegalovirus serostatus are also common contextual variables. CMV infection can expand differentiated T cell populations and contribute to immune profiles that resemble older immune states, which makes infection history an important confounder in immune-ageing interpretation. [9] [10]

Inflammatory and Protein-Based Immune Age Signals

Many immune ageing studies include inflammatory proteins because chronic low-grade inflammation often increases with age and overlaps with immunosenescence. IL-6, TNF-alpha, CRP, and related cytokine or chemokine panels are therefore treated as immune-ageing readouts, although they are not specific to ageing alone. [2] [7] [11]

The inflammatory clock iAge used soluble immune biomarkers to model inflammatory ageing and was linked with multimorbidity, frailty, immunosenescence, cardiovascular ageing, and exceptional longevity. CXCL9 was reported as a major contributor to that model, illustrating how a chemokine can become part of an immune-ageing score without being a complete measure of immune ageing by itself. [7]

High-Dimensional Immune Age Models

Immune age models combine many immune measurements into a statistical score. IMM-AGE, developed from longitudinal high-dimensional immune monitoring, described immune status better than chronological age in the study population and predicted all-cause mortality in the Framingham Heart Study beyond several established risk factors. [6]

More recent single-cell studies map immune ageing at finer resolution. Single-cell immune profiles have identified age-related changes in cell states, immune-cell heterogeneity, receptor features, and frailty associations, while integrated atlases are beginning to standardize how ageing-related immune cell populations are compared across datasets. [1] [8] [12]

Why Interpretation Is Hard

Immune biomarkers are highly context-dependent. A shifted T cell profile can reflect ageing biology, but it can also reflect CMV exposure, recent infection, vaccination, autoimmune disease, cancer, medication use, or chronic inflammatory disease. This makes immune biomarkers valuable in cohorts but difficult to interpret as isolated individual ageing measures. [1] [9] [10]

Model dependence is another limitation. An immune age score trained to predict chronological age, an inflammatory burden score trained around cytokines, and a frailty-associated single-cell signature may all be biologically informative while measuring different targets. Current biomarker frameworks caution that ageing biomarkers require careful validation against intended use, population, and outcome. [6] [7] [13]

Evidence Quality and Interpretation

Confidence is strong that the immune system changes substantially with age and that both innate and adaptive immune compartments contribute to immunosenescence and inflammaging. This is supported by reviews of immune ageing and by single-cell work mapping age-related immune-cell changes. [1] [2] [11]

Confidence is also strong that T cell composition, thymic output, and differentiated T cell markers are recurring immune-ageing signals. The evidence is strongest for population-level patterns rather than for a universal individual diagnostic threshold. [3] [4] [5]

Confidence is moderate that high-dimensional immune age models can provide useful cohort-level risk information, because studies such as IMM-AGE and iAge link immune scores with mortality or multiple ageing-related outcomes. Generalization depends on external validation and the match between the model's training target and the question being asked. [6] [7] [13]

Confidence is weaker for treating any single immune marker or immune age score as a complete biological age measurement. Immune status is shaped by antigen exposure, disease history, population background, and technical platform, so immune biomarkers usually work best as one domain inside broader ageing assessment. [1] [10] [13]

What This Does Not Mean

It does not mean immune ageing is the same thing as inflammation; the two overlap but are not interchangeable. [2] [11]
It does not mean a high immune age score identifies one precise mechanism of ageing. [6] [7]
It does not mean T cell markers such as CD57 or CD28 loss are universal clinical measures of biological age. [5]
It does not mean immune biomarkers can be interpreted without infection history, assay platform, and population context. [1] [10]

Practical Interpretation Examples

If naive T cells are lower in an older cohort: that can fit thymic involution and adaptive immune ageing, but it should be interpreted alongside memory T cell expansion, CMV status, and study design. [3] [4] [10]
If an immune age score predicts mortality: that supports prognostic value in the studied population, but it does not prove that the score captures every dimension of biological ageing. [6] [13]
If a cytokine-based inflammatory clock is elevated: that may indicate higher inflammatory immune burden, but cytokines and chemokines can also reflect disease, infection, and non-ageing physiology. [7] [11]

Summary

Immune ageing biomarkers are useful because the immune system changes across cell composition, inflammatory signaling, receptor diversity, and functional state with age. Their strongest role is in describing immune-system domains of ageing and stratifying cohort-level risk. Their main limitation is interpretation: immune measurements are strongly shaped by infection history, inflammatory disease, technical platform, and the specific model or marker being used. [1] [6] [7] [13]

References

Mogilenko, D. A., Shchukina, I., & Artyomov, M. N. (2022). Immune ageing at single-cell resolution. Nature Reviews Immunology. https://www.nature.com/articles/s41577-021-00646-4
Fulop, T., et al. (2018). Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?. Frontiers in Immunology. https://pmc.ncbi.nlm.nih.gov/articles/PMC5767595/
Palmer, D. B. (2013). The Effect of Age on Thymic Function. Frontiers in Immunology. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00316/full
Nikolich-Zugich, J. (2018). The twilight of immunity: emerging concepts in aging of the immune system. Nature Immunology. https://www.nature.com/articles/s41590-017-0006-x
Rodriguez, I. J., et al. (2021). Immunosenescence Study of T Cells: A Systematic Review. Frontiers in Immunology. https://pmc.ncbi.nlm.nih.gov/articles/PMC7843425/
Alpert, A., et al. (2019). A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nature Medicine. https://www.nature.com/articles/s41591-019-0381-y
Sayed, N., et al. (2021). An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nature Aging. https://www.nature.com/articles/s43587-021-00082-y
Luo, O. J., et al. (2022). Multidimensional single-cell analysis of human peripheral blood reveals characteristic features of the immune system landscape in aging and frailty. Nature Aging. https://www.nature.com/articles/s43587-022-00198-9
Pawelec, G. (2020). The human immunosenescence phenotype: does it exist?. Seminars in Immunopathology. https://link.springer.com/article/10.1007/s00281-020-00810-3
Turner, J. E., et al. (2014). Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young adults. Age. https://pubmed.ncbi.nlm.nih.gov/23846127/
Franceschi, C., et al. (2018). Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30046148/
Filippov, I., Schauser, L., & Peterson, P. (2024). An integrated single-cell atlas of blood immune cells in aging. npj Aging. https://www.nature.com/articles/s41514-024-00185-x
Moqri, M., et al. (2023). Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. https://pmc.ncbi.nlm.nih.gov/articles/PMC11088934/

Educational Disclaimer

This content is provided for educational purposes only and does not constitute medical advice.